- Home
- TRIP vs COLL Comparison
TRIP vs COLL Comparison
Compare TRIP & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TRIP | COLL |
|---|---|---|
| Founded | 2000 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | 2011 | 2015 |
Fundamental Metrics
Financial Performance| Metric | TRIP | COLL |
|---|---|---|
| Price | $8.93 | $22.63 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 13 | 5 |
| Target Price | $14.40 | ★ $51.40 |
| AVG Volume (30 Days) | ★ 3.5M | 806.6K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 675.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,556,000,000.00 | $780,567,000.00 |
| Revenue This Year | $3.33 | $8.01 |
| Revenue Next Year | $5.12 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 23.62 |
| 52 Week Low | $8.41 | $21.65 |
| 52 Week High | $19.45 | $50.79 |
Technical Indicators
Market Signals| Indicator | TRIP | COLL |
|---|---|---|
| Relative Strength Index (RSI) | 32.72 | 28.57 |
| Support Level | $8.41 | N/A |
| Resistance Level | $11.76 | $35.33 |
| Average True Range (ATR) | 0.35 | 0.88 |
| MACD | 0.09 | 0.13 |
| Stochastic Oscillator | 35.74 | 26.24 |
Price Performance
Historical ComparisonAbout TRIP TripAdvisor Inc.
Tripadvisor is the world's leading travel metasearch company. Its platform offers 1 billion reviews and information on several million accommodations, experiences, airlines, and cruises. In 2025, 42% of revenue came from the company's core Hotel and Other segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 46% of revenue in 2025. The company is selling TheFork, its dining brand, which represented 12% of sales.
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.